Overview

Ph2 Gem/Nov/Rituxan Rel/Ref MantleCell

Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
To determine the efficacy (response rate) produced by the combination of Gemzar, Novantrone, and Rituxan in relapsed or refractory MCL
Phase:
Phase 2
Details
Lead Sponsor:
US Oncology Research
Collaborator:
Eli Lilly and Company
Treatments:
Gemcitabine
Mitoxantrone
Rituximab